Antonietta Colatrella

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)

Massimo Breccia, Pier Paolo Olimpieri, Odoardo Maria Olimpieri et al. · Cancer Medicine · 2020 · 40 citations · Full text

Medicine, Oncology, Pharmacology +9

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries

Marcello Arca, Simone Celant, Pier Paolo Olimpieri et al. · Journal of the American Heart Association · 2023 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Contraception in diabetic women: an Italian study

Angela Napoli, Antonietta Colatrella, R. M. Botta et al. · Diabetes Research and Clinical Practice · 2004 · 25 citations

Medicine, Endocrinology, Gynecology +13

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

Massimo Breccia, Simone Celant, Pier Paolo Olimpieri et al. · Annals of Hematology · 2021 · 18 citations

Medicine, Oncology, Pharmacology +12

Continuous Glucose Monitoring During Breastfeeding in Women with Recent Gestational Diabetes Mellitus

Antonietta Colatrella, Marialuisa Framarino‐dei‐Malatesta, Vincenzo Toscano et al. · Diabetes Technology & Therapeutics · 2012 · 17 citations

Public Health, Endocrinology, Maternal Health +17